000181390 001__ 181390
000181390 005__ 20251118115334.0
000181390 0247_ $$2doi$$a10.1016/j.jhep.2022.07.029
000181390 0247_ $$2pmid$$apmid:35988690
000181390 0247_ $$2ISSN$$a0168-8278
000181390 0247_ $$2ISSN$$a1600-0641
000181390 0247_ $$2altmetric$$aaltmetric:134728824
000181390 037__ $$aDKFZ-2022-01958
000181390 041__ $$aEnglish
000181390 082__ $$a610
000181390 1001_ $$aRosenberg, Nofar$$b0
000181390 245__ $$aCombined hepatocellular-cholangiocarcinoma derives from liver progenitor cells and depends on senescence and IL6 trans-signaling.
000181390 260__ $$a[S.l.]$$bWiley-Blackwell$$c2022
000181390 3367_ $$2DRIVER$$aarticle
000181390 3367_ $$2DataCite$$aOutput Types/Journal article
000181390 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1763463203_1939189
000181390 3367_ $$2BibTeX$$aARTICLE
000181390 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000181390 3367_ $$00$$2EndNote$$aJournal Article
000181390 500__ $$a2022 Dec;77(6):1631-1641 / #DKFZ-MOST-Ca197#
000181390 520__ $$aPrimary liver cancers include: Hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (CCA) and combined HCC-CCA tumors (cHCC-CCA). It has been suggested, but not unequivocally proven, that hepatic progenitor cells (HPCs) can contribute to hepatocarcinogenesis. We aimed to determine whether HPCs contribute to HCC, cHCC-CCA or both types of tumors.To trace progenitor cells during hepatocarcinogenesis, we generated Mdr2-KO mice that harbor an YFP reporter gene driven by the Foxl1 promoter which is expressed specifically in progenitor cells. These mice (Mdr2-KOFoxl1-CRE;RosaYFP) develop chronic inflammation and HCCs by the age of 14-16 months, followed by cHCC-CCA tumors at the age of 18 months, as we have first observed.In this Mdr2-KOFoxl1-CRE;RosaYFP mouse model, liver progenitor cells are the source of cHCC-CCA tumors, but not the source of HCC. Ablating the progenitors, caused reduction of cHCC-CCA tumors but did not affect HCCs. RNA-seq revealed enrichment of the IL6 signaling pathway in cHCC-CCA tumors compared to HCC tumors. ScRNA-seq analysis revealed that IL6 is expressed from immune and parenchymal cells in senescence, and that IL6 is part of the senescence-associated secretory phenotype (SASP). Administration of anti-IL6 Ab to Mdr2-KOFoxl1-CRE;RosaYFP mice, inhibited the development of cHCC-CCA tumors. By blocking IL6 trans-signaling, cHCC-CCA tumors decreased in number and size, indicating that cHCC-CCA is dependent on IL6 trans-signaling. Furthermore, the administration of a senolytic agent inhibited IL6 and the development of cHCC-CCA tumors.Our results demonstrate that cHCC-CCA, but not HCC tumors, originate from HPCs, and that IL6, which derives in part from cells in senescence, plays an important role in this process via IL6 trans-signaling. These findings could enhance new therapeutic approaches for cHCC-CCA liver cancer.Combined hepatocellular carcinoma - cholangiocarcinoma is the third prevalent liver cancer. We show that the source of this tumor is the liver tissue stem cells and that, this tumor type is dependent on an inflammatory signaling of IL6 and can be inhibited by blocking IL6 signaling or using a senolytic agent.
000181390 536__ $$0G:(DE-HGF)POF4-316$$a316 - Infektionen, Entzündung und Krebs (POF4-316)$$cPOF4-316$$fPOF IV$$x0
000181390 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000181390 650_7 $$2Other$$aCancer stem cells
000181390 650_7 $$2Other$$aHepatocarcinogenesis
000181390 650_7 $$2Other$$aInflammation induced cancer
000181390 650_7 $$2Other$$aOval cells
000181390 7001_ $$aVan Haele, Matthias$$b1
000181390 7001_ $$aLanton, Tali$$b2
000181390 7001_ $$aBrashi, Neta$$b3
000181390 7001_ $$aBromberg, Zohar$$b4
000181390 7001_ $$aAdler, Hanan$$b5
000181390 7001_ $$aGiladi, Hilla$$b6
000181390 7001_ $$aPeled, Amnon$$b7
000181390 7001_ $$aGoldenberg, Daniel S$$b8
000181390 7001_ $$aAxelrod, Jonathan H$$b9
000181390 7001_ $$aSimerzin, Alina$$b10
000181390 7001_ $$aChai, Chofit$$b11
000181390 7001_ $$aPaldor, Mor$$b12
000181390 7001_ $$aMarkezana, Auerlia$$b13
000181390 7001_ $$aYaish, Dayana$$b14
000181390 7001_ $$aShemulian, Zohar$$b15
000181390 7001_ $$aGross, Dvora$$b16
000181390 7001_ $$aBarnoy, Shanny$$b17
000181390 7001_ $$aGefen, Maytal$$b18
000181390 7001_ $$aAmran, Osher$$b19
000181390 7001_ $$aClaerhout, Sofie$$b20
000181390 7001_ $$0P:(DE-HGF)0$$aFernández-Vaquero, Mirian$$b21
000181390 7001_ $$0P:(DE-HGF)0$$aGarcía-Beccaria, María$$b22
000181390 7001_ $$0P:(DE-He78)92c93319837b4b915db8393795faf0b6$$aHeide, Danijela$$b23$$udkfz
000181390 7001_ $$aShoshkes-Carmel, Michal$$b24
000181390 7001_ $$aSchmidt Arras, Dirk$$b25
000181390 7001_ $$aElgavish, Sharona$$b26
000181390 7001_ $$aNevo, Yuval$$b27
000181390 7001_ $$aBenyamini, Hadar$$b28
000181390 7001_ $$aTirnitz-Parker, Janina E E$$b29
000181390 7001_ $$aSanchez, Aranzazu$$b30
000181390 7001_ $$aHerrera, Blanca$$b31
000181390 7001_ $$aSafadi, Rifaat$$b32
000181390 7001_ $$aKaestner, Klaus H$$b33
000181390 7001_ $$aRose-John, Stefan$$b34
000181390 7001_ $$aRoskams, Tania$$b35
000181390 7001_ $$aHeikenwalder, Mathias$$b36
000181390 7001_ $$aGalun, Eithan$$b37
000181390 773__ $$0PERI:(DE-600)2027112-8$$a10.1016/j.jhep.2022.07.029$$gp. S0168827822029956$$n6$$p1631-1641$$tJournal of hepatology$$v77$$x0168-8278$$y2022
000181390 909CO $$ooai:inrepo02.dkfz.de:181390$$pVDB
000181390 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b21$$kDKFZ
000181390 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b22$$kDKFZ
000181390 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)92c93319837b4b915db8393795faf0b6$$aDeutsches Krebsforschungszentrum$$b23$$kDKFZ
000181390 9131_ $$0G:(DE-HGF)POF4-316$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfektionen, Entzündung und Krebs$$x0
000181390 9141_ $$y2022
000181390 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-29
000181390 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-29
000181390 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-29
000181390 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-09$$wger
000181390 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ HEPATOL : 2021$$d2022-11-09
000181390 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-09
000181390 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-09
000181390 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-09
000181390 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-09
000181390 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-09
000181390 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-09
000181390 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-09
000181390 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-09
000181390 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-09
000181390 915__ $$0StatID:(DE-HGF)9930$$2StatID$$aIF >= 30$$bJ HEPATOL : 2021$$d2022-11-09
000181390 9201_ $$0I:(DE-He78)F180-20160331$$kF180$$lChronische Entzündung und Krebs$$x0
000181390 980__ $$ajournal
000181390 980__ $$aVDB
000181390 980__ $$aI:(DE-He78)F180-20160331
000181390 980__ $$aUNRESTRICTED